Significant Transplantation-Related Mortality from Respiratory Virus Infections within the First One Hundred Days in Children after Hematopoietic Stem Cell Transplantation

被引:47
作者
Hutspardol, Sakara [1 ]
Essa, Mohammed [2 ]
Richardson, Susan [3 ]
Schechter, Tal [1 ]
Ali, Muhammad [1 ]
Krueger, Joerg [1 ]
Fujii, Hisaki [1 ]
Egeler, R. Maarten [1 ]
Gassas, Adam [1 ]
机构
[1] Univ Toronto, Hosp Sick Children, Div Haematol Oncol BMT, Toronto, ON M5S 1A1, Canada
[2] King Saud Bin Abdulaziz Univ Hlth Sci, King Abdullah Specialized Childrens Hosp, Div Haematol Oncol SCT, Riyadh, Saudi Arabia
[3] Univ Toronto, Hosp Sick Children, Div Microbiol, Toronto, ON M5S 1A1, Canada
关键词
Respiratory virus infection; Hematopoietic stem cell transplantation; Children; Mortality; PARAINFLUENZA VIRUS; SYNCYTIAL VIRUS; RISK-FACTORS; INFLUENZA VACCINATION; ADENOVIRUS INFECTIONS; VIRAL-INFECTIONS; IMMUNOCOMPROMISED PATIENTS; HUMAN METAPNEUMOVIRUS; RECIPIENTS; DISEASE;
D O I
10.1016/j.bbmt.2015.06.015
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Respiratory viral infections (RVI) are important in hematopoietic stem cell transplantations (HSCT) and knowledge regarding incidence, morbidity, mortality, and long-term pulmonary complications is limited. We report a study to evaluate incidence and outcomes, both short and long-term, of RVI in children receiving HSCT. Between January 2000 and December 2012, 844 patients underwent hematopoietic stem cell transplantation (HSCT) at the Hospital for Sick Children: 491 were allogeneic and 353 were autologous. When screening for causes of death in the first year after HSCT in the 844 patients, we found that RVI as a cause of death was only evident in the first 100 days after HSCT. Fifty-four (6.5%) patients were found to have an RVI within the first 100 days after HSCT (allogeneic = 32, autologous = 22). Upper and lower respiratory tract infections were documented in 31 (57%) and 23 (43%) patients, respectively. Viruses were parainfluenza (35%), respiratory syncytial virus (28%), influenza (22%), adenovirus (7%), human metapneumovirus (4%), coronavirus (2%), and rhinovirus (2%). Three patients relapsed with their primary disease before day 100 and were excluded. The overall mortality for the remaining 51 patients was 10% (allogeneic = 4, autologous = 1). All 5 deaths were directly attributable to RVI and all 5 deaths occurred in patients with a lower respiratory tract infection. The remaining patients were followed for a median of 4.3 years (range, 1.4 to 11.8) and no chronic pulmonary complications were observed. A clear seasonal pattern for contracting RVI was evident with 65% of total RVI occurring between October and March (35 of 427 versus 19 of 417, P = .03). Given the significant mortality from RVI and the challenges in preventing them, choosing the time to start HSCT, whenever possible, may help prevent RVI and improve outcomes. (C) 2015 American Society for Blood and Marrow Transplantation.
引用
收藏
页码:1802 / 1807
页数:6
相关论文
共 48 条
[1]   Safety and tolerability of cidofovir in high-risk pediatric patients [J].
Bhadri, V. A. ;
Lee-Horn, L. ;
Shaw, P. J. .
TRANSPLANT INFECTIOUS DISEASE, 2009, 11 (04) :373-379
[2]   Adenovirus infection in hematopoietic stem cell transplantation: Effect of ganciclovir and impact on survival [J].
Bruno, B ;
Gooley, T ;
Hackman, RC ;
Davis, C ;
Corey, L ;
Boeckh, M .
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2003, 9 (05) :341-352
[3]   Human metapneumovirus in a haematopoietic stem cell transplant recipient with fatal lower respiratory tract disease [J].
Cane, PA ;
van den Hoogen, BG ;
Chakrabarti, S ;
Fegan, CD ;
Osterhaus, ADME .
BONE MARROW TRANSPLANTATION, 2003, 31 (04) :309-310
[4]   Adenovirus infections following allogeneic stem cell transplantation: incidence and outcome in relation to graft manipulation, immunosuppression, and immune recovery [J].
Chakrabarti, S ;
Mautner, V ;
Osman, H ;
Collingham, KE ;
Fegan, CD ;
Klapper, PE ;
Moss, PAH ;
Milligan, DW .
BLOOD, 2002, 100 (05) :1619-1627
[5]   Respiratory viral infections in adults with hematologic malignancies and human stem cell transplantation recipients - A retrospective study at a major cancer center [J].
Chemaly, Roy F. ;
Ghosh, Shubhra ;
Bodey, Gerald P. ;
Rohatgi, Nidhi ;
Safdar, Amar ;
Keating, Michael J. ;
Champlin, Richard E. ;
Aguilera, Elizabeth A. ;
Tarrand, Jeffrey J. ;
Raad, Issam I. .
MEDICINE, 2006, 85 (05) :278-287
[6]   Infections after T-replete haploidentical transplantation and high-dose cyclophosphamide as graft-versus-host disease prophylaxis [J].
Crocchiolo, R. ;
Bramanti, S. ;
Vai, A. ;
Sarina, B. ;
Mineri, R. ;
Casari, E. ;
Tordato, F. ;
Mauro, E. ;
Timofeeva, I. ;
Lugli, E. ;
Mavilio, D. ;
Carlo-Stella, C. ;
Santoro, A. ;
Castagna, L. .
TRANSPLANT INFECTIOUS DISEASE, 2015, 17 (02) :242-249
[7]   Palivizumab treatment of respiratory syncytial virus infection after allogeneic hematopoietic stem cell transplantation [J].
de Fontbrune, Flore Sicre ;
Robin, Marie ;
Porcher, Raphael ;
Scieux, Catherine ;
de latour, Regis Peffault ;
Ferry, Christele ;
Rocha, Vanderson ;
Boudjedir, Karim ;
Devergie, Agnes ;
Bergeron, Anne ;
Gluckman, Eliane ;
Azoulay, Elie ;
Lapalu, Jordane ;
Socie, Gerard ;
Ribaud, Patricia .
CLINICAL INFECTIOUS DISEASES, 2007, 45 (08) :1019-1024
[8]   Persistent symptomless human metapneumovirus infection in hematopoietic stem cell transplant recipients [J].
Debiaggi, Maurizia ;
Canducci, Filippo ;
Sampaolo, Michela ;
Marinozzi, Maria Chiara ;
Parea, Maurizio ;
Terulla, Cristina ;
Colombo, Anna Amelia ;
Alessandrino, Emilio Paolo ;
Bragotti, Letizia Zenone ;
Arghittu, Milena ;
Goglio, Antonio ;
Migliavacca, Roberta ;
Romero, Egidio ;
Clementi, Massimo .
JOURNAL OF INFECTIOUS DISEASES, 2006, 194 (04) :474-478
[9]   Comparable humoral response after two doses of adjuvanted influenza A/H1N1pdm2009 vaccine or natural infection in allogeneic stem cell transplant recipients [J].
Dhedin, Nathalie ;
Krivine, Anne ;
Le Corre, Nicole ;
Mallet, Alain ;
Lioure, Bruno ;
Bay, Jacques-Olivier ;
Rubio, Marie-Therese ;
Agape, Philippe ;
Thiebaut, Anne ;
Le Goff, Jerome ;
Autran, Brigitte ;
Ribaud, Patricia .
VACCINE, 2014, 32 (05) :585-591
[10]   CMV reactivation after allogeneic HCT and relapse risk: evidence for early protection in acute myeloid leukemia [J].
Green, Margaret L. ;
Leisenring, Wendy M. ;
Xie, Hu ;
Walter, Roland B. ;
Mielcarek, Marco ;
Sandmaier, Brenda M. ;
Riddell, Stanley R. ;
Boeckh, Michael .
BLOOD, 2013, 122 (07) :1316-1324